Hemostatic microspheres
View Patent ↗Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
1. A hemostatic composition comprising a plurality of porous gelatin microspheres, thrombin, a wetting agent, and a suspending agent;
wherein the wetting agent and the suspending agent are present in a ratio of microspheres:the wetting agent and the suspending agent of 3:1 to 60:1 (w/w);
wherein the gelatin is cross-linked gelatin; wherein the porous gelatin microspheres have a diameter from about 50 μm to about 500 μm, inclusive, when fully hydrated; wherein the porous gelatin microspheres contain pores having a pore diameter from about 15 μm to about 25 μm, inclusive; wherein the thrombin concentration is in a range of about 1,000 IU to about 2,000 IU per mL of rehydrated microsphere gel and a high level of thrombin is released from the hemostatic composition to yield a homogenous clot; wherein the hemostatic composition, when fully hydrated, remains flowable for at least 90 minutes, and
wherein the wetting agent is poloxamer 188 and the suspending agent is carboxymethylcellulose.
2. The hemostatic composition of claim 1 , wherein said porous gelatin microspheres have a diameter from about 110 μm to about 400 μm, inclusive, when fully hydrated.
3. The hemostatic composition of claim 1 , wherein said composition is a dry powder.
4. The hemostatic composition of claim 1 , wherein said composition is a gel that is at least partially hydrated.
5. The hemostatic composition of claim 4 , wherein said composition is hydrated with a diluent that includes or consists of plasma.
6. The hemostatic composition of claim 1 , wherein said composition is a partially hydrated gel or a fully hydrated gel.
7. The hemostatic composition of claim 6 , wherein said composition is hydrated with a diluent that includes or consists of plasma.
8. The hemostatic composition of claim 1 , wherein said hemostatic composition is present within the barrel of a syringe.
9. A hemostatic composition delivery device comprising a first syringe and a second syringe wherein said first syringe contains a dry powder hemostatic composition comprising:
porous gelatin microspheres wherein the gelatin is cross-linked;
a wetting agent; and
a suspending agent;
wherein the wetting agent and the suspending agent are present in a ratio of microspheres:the wetting agent and the suspending agent of 3:1 to 60:1 (w/w);
wherein the porous gelatin microspheres have a diameter from about 50 μm to about 500 μm, inclusive, when fully hydrated;
wherein the porous gelatin microspheres contain pores having a pore diameter from about 15 μm to about 25 μm, inclusive; and
wherein the wetting agent is poloxamer 188 and the suspending agent is carboxymethylcellulose;
wherein said second syringe comprises a diluent comprising thrombin; wherein the thrombin concentration is in a range of about 1,000 IU to about 5,000 IU per mL of rehydrated microsphere gel and a high level of thrombin is released from the hemostatic composition to yield a homogenous clot; and
wherein the hemostatic composition, when fully hydrated, remains flowable for at least 90 minutes.
10. The hemostatic composition delivery device of claim 9 , wherein said hemostatic composition is a dry powder.
11. The hemostatic composition delivery device of claim 9 , wherein said diluent contains or is plasma.
12. The hemostatic composition delivery device of claim 9 wherein said second syringe and said first syringe containing a hemostatic composition are interconnected.
13. The hemostatic composition delivery device of claim 12 , wherein said syringes are interconnected by a male/female leur lock system.
14. A hemostatic composition comprising a plurality of porous gelatin microspheres, thrombin, a wetting agent, and a suspending agent;
wherein the wetting agent and the suspending agent are present in a ratio of microspheres:the wetting agent and the suspending agent of 3:1 to 60:1 (w/w);
wherein the gelatin is cross-linked gelatin; wherein the porous gelatin microspheres have a diameter from about 50 μm to about 500 μm, inclusive, when fully hydrated; wherein the porous gelatin microspheres contain pores having a pore diameter from about 15 μm to about 25 μm, inclusive; wherein the thrombin concentration is in a range of about 2,000 IU to about 5,000 IU per mL of rehydrated microsphere gel and a high level of thrombin is released from the hemostatic composition to yield a homogenous clot; wherein the hemostatic composition, when fully hydrated, remains flowable for at least 90 minutes, and
wherein the wetting agent is poloxamer 188 and the suspending agent is carboxymethylcellulose.